Organization (Academic)
Weizmann Institute of Science
ClinicalTrials.gov lists Weizmann Institute of Science as lead sponsor of 13 trials. It has 2 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Weizmann Institute of Science: 13 lead-sponsored trials and 1 legal-entity registration.
Disease areas (59)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Glucose Intolerance | 4 |
| Hyperglycemia | 4 |
| Crohn Disease | 3 |
| Diabetes Mellitus | 3 |
| Inflammatory Bowel Diseases | 3 |
Showing 5 of 59 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 5 |
| 2021 | 7 |
| 2020 | 7 |
| 2019 | 1 |
| 2018 | 6 |
| 2017 | 9 |
Showing 10 of 18 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Antibiotic Treatment | Obesity | Not reported | 1 |
| Antibiotic Treatment | Weight Loss | Not reported | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| Anhydrous glucose | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=5) | 2 of 3 on time (n=3) |
Journals published in (69)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Nature | 8 |
| Science (New York, N.Y.) | 6 |
| The New England journal of medicine | 4 |
| Cell | 3 |
| Diabetes care | 3 |
Showing 5 of 69 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,205 | 130 | 2025-12-30 |
Financing and grant events (3)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-04-07 | NIH grant | 179,791 | Reporter |
| 2024-05-30 | NIH grant | 181,532 | Reporter |
| 2023-04-28 | NIH grant | 191,085 | Reporter |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| HaEmek Medical Center, Israel | Co sponsors trial with | 2 |
| Tel Aviv Sourasky Medical Center | Co sponsors trial with | 2 |
| Federico II University | Co sponsors trial with | 1 |
| University of Hamburg-Eppendorf | Co sponsors trial with | 1 |
| Weill Medical College of Cornell University | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (1,270)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 1,270 events.
Biomarker capability evidence (39)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CALR | Trial sponsor | Named in trial inclusion criteria |
| CYP19A1 | Trial collaborator | Named in trial inclusion criteria |
| DPP4 | Trial collaborator | Named in trial inclusion criteria |
| FGF3 | Trial collaborator | Named in trial inclusion criteria |
| GNRH1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 39 evidence rows.
Biomarkers this organization publishes on (551)
Shown in this order: most publications first.
Showing 5 of 551 biomarkers.
On Scientist.com
Weizmann Institute of Science is listed as a research supplier in the Scientist.com network.
Service areas
The Weizmann Institute of Science is one of the world’s leading multidisciplinary research institutions. Hundreds of scientists, laboratory technicians and research students working on its lushly landscaped campus embark daily on fascinating journeys into the unknown, seeking to improve our understanding of nature and our place within it. Lettuce fieldGuiding these scientists is the spirit of inquiry so characteristic of the human race. It is this spirit that propelled humans upward along the evolutionary ladder, helping them reach their utmost heights. It prompted humankind to pursue...
Show the full description
The Weizmann Institute of Science is one of the world’s leading multidisciplinary research institutions. Hundreds of scientists, laboratory technicians and research students working on its lushly landscaped campus embark daily on fascinating journeys into the unknown, seeking to improve our understanding of nature and our place within it.
Lettuce fieldGuiding these scientists is the spirit of inquiry so characteristic of the human race. It is this spirit that propelled humans upward along the evolutionary ladder, helping them reach their utmost heights.
It prompted humankind to pursue agriculture, learn to build lodgings, invent writing, harness electricity to power emerging technologies, observe distant galaxies, design drugs to combat various diseases, develop new materials and decipher the genetic code embedded in all the plants and animals on Earth.
The quest to maintain this increasing momentum compels Weizmann Institute scientists to seek out places that have not yet been reached by the human mind. What awaits us in these places? No one has the answer to this question. But one thing is certain – the journey fired by curiosity will lead onward to a better future.
- Website
- www.weizmann.ac.il
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Weizmann Institute of Science on Scientist.com
For prices, more details, or to contact Weizmann Institute of Science, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.